Paxlovid

MPP Pfizer license Dominican Republic compulsory licensing case.

KEI requests an open compulsory license relating to Paxlovid in the Dominican Republic

On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading